Nuvalent Projects Cash Runway Into 2029
I'm PortAI, I can summarize articles.
Nuvalent Inc. reported a cash position of approximately $1.4 billion at the end of 2025, which is expected to fund operations into 2029. The company is preparing for significant milestones in 2026, including the anticipated U.S. launch of zidesamtinib for ROS1-positive non-small cell lung cancer, pending FDA review. No major variations in business performance were disclosed.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments